VIAL
Home/Compounds/Hexarelin
PeptideGrey AreaPreclinical

Hexarelin

About

About Hexarelin

Hexarelin is one of the most potent growth hormone secretagogues developed, producing significantly higher GH peaks than ipamorelin or GHRP-2. However, it causes rapid receptor desensitization with continuous use, requiring cycling protocols. It also has cardioprotective properties independent of GH release. Available as a research/compounded peptide.

Science

Mechanism of Action

Binds GHSR-1a with very high affinity, producing maximal GH pulse amplification; independent cardioprotective effects are mediated through CD36 receptors in myocardial tissue.

Dosing

Typical Protocol

100–200 mcg subcutaneous injection 2x daily; cycle 4–6 weeks on with 4-week breaks to prevent desensitization.

⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.

Regulatory

Legal Status in 2026

Grey Area

This compound occupies a regulatory grey area in 2026. It is neither explicitly FDA-approved nor clearly illegal for personal use, but it lacks formal clinical approval and may not be legally sold for human use in all contexts. Proceed with caution: source quality is variable, and regulatory status can change. Always consult a physician.

Evidence

Evidence Tier

Preclinical

Evidence primarily from animal studies, cell cultures, or small pilot human trials. Results are promising but have not yet been confirmed in large-scale human RCTs. Effects in humans may differ from animal models.

Find a Verified Provider

See which Vial-verified providers offer Hexarelin — with trust scores, legal credentials, and pricing transparency.

Browse all verified providers →